Who
Benjamin Halladay
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Achieve Life Sciences; Chief Financial Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $171K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Dec 2022
- Last trade
- 5 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 6 Oct 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 5 Oct 2026filed 6 Oct 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —705,410 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —213,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —213,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —221,270 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —221,270 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —705,410 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K10,773 at $3.16 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $34K10,773 at $3.16 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K6,424 at $2.71 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $17K6,424 at $2.71 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code A | —247,430 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —221,270 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —221,270 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Code A | —247,430 at $0.00 | filing |
| 17 Dec 2025filed 18 Dec 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $27K7,337 at $3.67 | filing |
| 17 Sep 2025filed 18 Sep 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $20K7,046 at $2.81 | filing |
News
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officermanilatimes.net · 1 Oct 2026
1 headline in the last 90 days name Benjamin Halladay; no company of theirs resolves to a name we track.